SCHEMBL1407428

SCHEMBL1407428

COc1ccc(-c2c3cccc(F)c3nn2Cc2ccc(F)cc2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.47
NR1H3 Q13133 4/20 0.47
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
NR1I2 O75469 2/20 0.40
NR3C1 P04150 2/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
NTSR1 P30989 1/20 0.39
HTT P42858 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TLR9 Q9NR96 1/20 0.39
CYP1A1 P04798 2/20 0.39
CYP1B1 Q16678 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407475 0.93 NR1H2 (0.46) NR1H2NR1H3SMN1; SMN2KDM4EALDH1A1
SCHEMBL1407455 0.93 NR1H2 (0.45) NR1H2NR1H3KMT2AMEN1KDM4E
SCHEMBL1407321 0.91 NR1H2 (0.47) NR1H2NR1H3KMT2ASMN1; SMN2MEN1
SCHEMBL1407316 0.91 P2RX7 (0.40) NR1H2NR1H3KMT2AMEN1KDM4E
SCHEMBL1407448 0.90 NR1H2 (0.47) NR1H2NR1H3KMT2ASMN1; SMN2MEN1
SCHEMBL1408297 0.88 NR1H2 (0.43) NR1H2NR1H3KMT2ASMN1; SMN2MEN1
SCHEMBL1407447 0.86 NR1H2 (0.47) NR1H2NR1H3KMT2ASMN1; SMN2MEN1
SCHEMBL1407384 0.86 KMT2A (0.48) NR1H2NR1H3KMT2AMEN1KDM4E
SCHEMBL1407762 0.85 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1KDM4E
SCHEMBL4030775 0.83 CYP1A1 (0.39) KMT2ASMN1; SMN2MEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885KMT2A 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.